JCRB1426 KYSE190
Cell information
Important Notice(s)Announcement of unavailability of KYSE series cell lines to oversea users outside of Japan
Cell type：general cells (View Pricing Information)
| JCRB No. | JCRB1426 | Cell Name | KYSE190 |
|---|---|---|---|
| Profile | Human well differentiated squamous cell carcinoma cell line established from esophageal cancer. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | F | Age | 69 |
| Identity | available | Tissue for Primary Cancer | esophagus |
| Case history | well differentiated squamous cell carcinoma, stage 2b | Metastasis | Yes |
| Tissue Metastasized | Genetics | ||
| Life Span | infinite | Crisis PDL | |
| Morphology | epithelial-like | Character | T2N1M0 stage 2b |
| Classify | tumor | Established by | Shimada, Y. |
| Registered by | Shimada, Y. | Regulation for Distribution | |
| Comment | Year | 2011 | |
| Medium | Ham's F12 medium + RPMI1640 medium (1 to 1 mix) with 2% fetal calf serum (original description). Current medium for propagation; RPMI1640/F12 (1:1 mix) + 5 % FBS. | Methods for Passages | Cells harvested after treatment with trypsin and EDTA. |
| Cell Number on Passage | split ratio = 1/5 | Race | |
| CO2 Conc. | 5% | Tissue Sampling | esophagus |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:21044961 | MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). Tsuchiya S,Fujiwara T,Sato F,Shimada Y,Tanaka E,Sakai Y,Shimizu K,Tsujimoto G J Biol Chem. 2011 Jan 7;286(1):420-8 |
| Pubmed id:16951226 | The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma. Okumura T,Tsunoda S,Mori Y,Ito T,Kikuchi K,Wang TC,Yasumoto S,Shimada Y Clin Cancer Res. 2006 Sep 1;12(17):5096-103 |
| Pubmed id:17671398 | ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Tsunoda S,Okumura T,Ito T,Kondo K,Ortiz C,Tanaka E,Watanabe G,Itami A,Sakai Y,Shimada Y Oncology. 2006;71(3-4):251-8 |
| Pubmed id:15814639 | Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Hashimoto Y,Ito T,Inoue H,Okumura T,Tanaka E,Tsunoda S,Higashiyama M,Watanabe G,Imamura M,Shimada Y Clin Cancer Res. 2005 Apr 1;11(7):2597-605 |
| Pubmed id:12538476 | Cell culture in esophageal squamous cell carcinoma and the association with molecular markers. Shimada Y,Maeda M,Watanabe G,Yamasaki S,Komoto I,Kaganoi J,Kan T,Hashimoto Y,Imoto I,Inazawa J,Imamura M Clin Cancer Res. 2003 Jan;9(1):243-9 |
| Pubmed id:9033652 | Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines. Tanaka H,Shimada Y,Imamura M,Shibagaki I,Ishizaki K Int J Cancer. 1997 Feb 7;70(4):437-42 |
| Pubmed id:8575860 | Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors. Tanaka H,Shibagaki I,Shimada Y,Wagata T,Imamura M,Ishizaki K Int J Cancer. 1996 Jan 26;65(3):372-6 |
| Pubmed id:7913084 | Analysis of gene amplification and overexpression in human esophageal-carcinoma cell lines. Kanda Y,Nishiyama Y,Shimada Y,Imamura M,Nomura H,Hiai H,Fukumoto M Int J Cancer. 1994 Jul 15;58(2):291-7 |
| Pubmed id:1728357 | Characterization of 21 newly established esophageal cancer cell lines. Shimada Y,Imamura M,Wagata T,Yamaguchi N,Tobe T Cancer. 1992 Jan 15;69(2):277-84 |
| Images |
|---|
       |
| Movies |
|---|
|
LOT Information
| Cell No. | JCRB1426 | Cell Name | KYSE190 |
|---|---|---|---|
| LOT No. | 09092011 | Lot Specification | distribution |
| Medium | RPMI1640(GIBCO) and Ham's F12 medium(SIGMA)(1/1) with 5% heat inactivated fetal bovine serum(SIGMA027K03911) | Temperature | 37 C |
| Cell Density at Seeding | 0.24-1.0x10^5 cells/sq.cm | Methods for Passages | Cells were harvested after treatment with 0.25%trypsin(GIBCO) and 0.02% EDTA. |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 3.6x10^6 |
| Viability at cell freezing (%) | 91.1 | Antibiotics Used | free |
| Passage Number | p4* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:10 D13S317:11 D7S820:10,12 D16S539:9 VWA:16 TH01:6 AM:X TPOX:11 CSF1PO:11 |
| Adhesion | Yes | Exoteric Gene | NT |
| Medium for Freezing | Cell Banker BLC-1(Nihon Zenyaku Industries) | CO2 Conc. | 5 % |
| Viability immediately after thawing (%) | Additional information |
| Images |
|---|
|
|
| Cell No. | JCRB1426 | Cell Name | KYSE190 |
|---|---|---|---|
| LOT No. | 12172018 | Lot Specification | distribution |
| Medium | 1:1 mixture of RPMI 1640 medium and Ham's F12 medium with 5% fetal bovine serum (FBS; Sigma Cat. # 172012) | Temperature | 37 C |
| Cell Density at Seeding | 0.5 - 1 x 10^5 cells/mL | Methods for Passages | Cells were harvested after treatment wth 0.25% trypsin and 0.02% EDTA. |
| Doubling Time | approx. 31 hrs. | Cell Number in Vial (cells/1ml) | 2.4 x 10^6 |
| Viability at cell freezing (%) | 96.0 | Antibiotics Used | free |
| Passage Number | Unknown (7 at bank) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | Yes | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% FBS - RPMI1640/F12 | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 89.6 | Additional information |